Recombinant Human Erythropoeitin (Alfa Epo) is now widely available and widely used to maintain haemoglobin between 10-11 g/dL.
It is given three times per week at the end of haemodialysis session or as subcutaneous injection for those with Chronic Renal Failure (no renal replacement therapy) or those on Continuous Ambulatory Peritoneal Dialysis (CAPD).
Complications:
- hypertension
- convulsions
- hyperkalaemia
- transient ischaemic attack (TIA)
- clotting arteriovenous (A-V) fistulae
Articles of Interest
Schoener B, Borger J. Erythropoietin. [Updated 2020 Oct 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536997/.
Downloads
Physiology and Pharmacology of Erythropoeitin – Jelkmann (2013)
